Synopsis:
Asit Parikh, M.D., Ph.D., is the President and CEO of MOMA Therapeutics, a biotech company discovering the next generation of precision medicines by targeting highly dynamic proteins that underlie human disease. Asit discusses his experience and learnings being the CEO of a biotech for the first time and his approach to recruiting high quality talent. He also talks about the inherent risks in drug development, how he manages the emotional ups and downs, and provides his perspective on how drug development has changed and evolved over the last couple decades.
Biography:
Asit Parikh, M.D., Ph.D., joined MOMA in 2021 as President, Chief Executive Officer and member of the board of directors.
Asit brings to MOMA more than 20 years of academic and industry experience. Prior to MOMA, Asit served as senior vice president and head of Takeda’s gastroenterology unit from 2014 to 2020. Under his leadership, Takeda achieved global approvals for Entyvio® for ulcerative colitis and Crohn’s disease; European adult and U.S. pediatric approvals for Gattex®/Revestive® for short bowel syndrome; Japan and China approvals for Takecab®/Vocinti® for acid-related disorders; a European approval for Alofisel® for perianal fistulizing Crohn’s disease; and a U.S. approval for Motegrity® for chronic constipation. During this time, to ensure a sustainable pipeline, Asit oversaw the creation of a drug discovery unit focused on gastroenterology and liver diseases and identified and executed over 25 business development deals. These diverse transactions included regional and global licensing (eg Arrowhead A1AT), M&A (eg Tigenix SA) and company creation (eg Ambys Medicines).
Previously, Asit served as the general internal medicine franchise head at Takeda. Earlier, he held leadership roles in inflammation and oncology clinical development at Millennium Pharmaceuticals (acquired by Takeda in 2008). During his tenure at Millennium/Takeda, Asit was regularly recognized at the enterprise level for his inspirational leadership style, and as an identifier and developer of talent.
Asit remains actively engaged in the practice of medicine as a consulting gastroenterologist at Newton-Wellesley Hospital in Newton, Massachusetts, and serves as a board member of Ambys Medicines, Phathom Pharmaceuticals and Vanderbilt University School of Medicine, Basic Sciences.
Asit earned his Ph.D. in biochemistry and M.D. from Vanderbilt University, completed his internal medicine residency at the University of Pennsylvania and subspecialty training in gastroenterology at Massachusetts General Hospital. He performed postdoctoral research in cancer biology at the Massachusetts Institute of Technology.
Biotech 2050 Podcast